Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-017759
Filing Date
2022-11-14
Accepted
2022-11-14 16:12:12
Documents
50
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20220930x10q.htm   iXBRL 10-Q 783701
2 EX-31.1 tmb-20220930xex31d1.htm EX-31.1 12204
3 EX-31.2 tmb-20220930xex31d2.htm EX-31.2 12185
4 EX-32.1 tmb-20220930xex32d1.htm EX-32.1 6865
5 EX-32.2 tmb-20220930xex32d2.htm EX-32.2 6884
  Complete submission text file 0001558370-22-017759.txt   3383116

Data Files

Seq Description Document Type Size
6 EX-101.SCH tmb-20220930.xsd EX-101.SCH 27812
7 EX-101.CAL tmb-20220930_cal.xml EX-101.CAL 24013
8 EX-101.DEF tmb-20220930_def.xml EX-101.DEF 115099
9 EX-101.LAB tmb-20220930_lab.xml EX-101.LAB 261479
10 EX-101.PRE tmb-20220930_pre.xml EX-101.PRE 206011
44 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20220930x10q_htm.xml XML 408502
Mailing Address 44 MILTON AVENUE ALPHARETTA GA 30009
Business Address 44 MILTON AVENUE ALPHARETTA GA 30009 8666208655
Virios Therapeutics, Inc. (Filer) CIK: 0001818844 (see all company filings)

EIN.: 854314201 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39811 | Film No.: 221385382
SIC: 2834 Pharmaceutical Preparations